ClearPoint Neuro to Announce First Quarter 2023 Results May 11, 2023
SOLANA BEACH, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global therapy-enabling platform...
SOLANA BEACH, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global therapy-enabling platform...
PALO ALTO, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics,...
NEW YORK, April 28, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that...
PRINCETON, N.J., April 28, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced preliminary...
SHANGHAI, China and REDWOOD CITY, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX:...
Results published in peer-reviewed Cancer Research share novel insights into Chi3L1’s role in modulating Glioma stem cells and reinforces the...
Asserts Certara’s leadership in advancing the development and approval of new drugs for patientsPRINCETON, N.J., April 27, 2023 (GLOBE NEWSWIRE)...
Vincent Chiara, real estate entrepreneur and founder and President of Groupe Mach donates $1.4 million to the MUCH Foundation for...
WARRINGTON, Pa., April 27, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT) is a biotechnology...
NEW YORK, N.Y. and DURHAM, N.C., April 27, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a biotechnology company pioneering...
SINGAPORE and BETHESDA, Md., April 26, 2023 (GLOBE NEWSWIRE) -- AUM Biosciences Pte. Ltd. (“AUM”), a global clinical-stage biotechnology company...
SAB-185, a human IgG1 (polyclonal) antibody therapeutic candidate, demonstrated benefit in sustained symptom resolution in patients with Omicron variants of...
New Analysis Indicates No Drug-Drug Interactions (DDIs) of Clinical Concern are Predicted When Recommended Doses of Trudhesa and Gepants are...
SEATTLE and VANCOUVER, British Columbia, April 26, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical...
Submits Provisional Patent Application entitled “Nanoparticles Comprising Payloads and Their In Vivo Delivery.”BOSTON, April 26, 2023 (GLOBE NEWSWIRE) -- TransCode...
Providence, RI, April 25, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development...
VANCOUVER, British Columbia, April 25, 2023 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF...
Topline data anticipated in mid-2024 SIGNAL-AD builds on promising data from the Phase 2 SIGNAL Study in Huntington’s Disease ROCHESTER,...
CINCINNATI, April 25, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a biotechnology company spanning...
Promising preliminary antitumor activity with the combination demonstrated in heavily pretreated patients 47% ORR, 5.5 months mPFS observed with preferred...